The US FDA has approved a new indication for German drug major Bayer's Kogenate FS antihemophilic factor VIII (recombinant), for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A 

Although Kogenate is among Bayer's established pharmaceutical products (cleared for marketing in the 1990s), 2013 sales of the blood clotting drug still increased by 6.4% to 1.20 billion euros ($1.65 billion) on a currency-adjusted basis due to higher volumes.

For more details, go to: http://www.thepharmaletter.com/article/fda-approves-new-indication-for-bayer-s-kogenate